Pfizer’s coronavirus-related sales have dropped significantly, and the decline may continue next year. The company is working on new products like a flu vaccine and a weight loss therapy to rebound. Pfizer’s mRNA flu vaccine shows promise, potentially offering better efficacy than traditional flu shots. Additionally, the company has two promising candidates for cancer and weight loss treatments. Despite some challenges, Pfizer’s stock is currently undervalued and could see growth with the development of new blockbuster drugs. Investors should consider Pfizer’s potential for future returns.

Read more at Nasdaq MarketSite: Pfizer Is Still Struggling to Replace Its COVID Revenue. Here’s What We Could See From the Pharmaceutical Giant in 2026.